TCM
LVTX

Tang Capital Management’s LAVA Therapeutics LVTX Stock Holding History

Tang Capital Management’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-53,101
Closed -$88.1K – 188
2024
Q3 		$88.1K Buy
53,101
+47,992
+939% +$87.8K 0.01% 153
2024
Q2 		$9.2K Buy
+5,109
New +$13.5K ﹤0.01% 128
2024
Q1 		– Sell
-840,593
Closed -$1.33M – 117
2023
Q4 		$1.33M Buy
+840,593
New +$1.2M 0.12% 100

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
EGM
Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return

Tang Capital Management's LVTX Position: Q4 2024 in Review

Tang Capital Management sold out of LAVA Therapeutics (LVTX) in Q4 2024, closing a stake of 53,101 shares — an estimated $88.1K sold.

Tang Capital Management first reported a position in LVTX in Q4 2023 and held it in 3 quarters. The position peaked at $1.33M in Q4 2023. 22 funds tracked by Wall St. Rank hold LVTX as of Q4 2024.

  • Tang Capital Management reported no remaining LAVA Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Tang Capital Management sold 53,101 LAVA Therapeutics shares in Q4 2024, an estimated $88.1K.
  • Tang Capital Management first reported a position in LAVA Therapeutics in Q4 2023 and held it in 3 quarters.
  • Tang Capital Management's LAVA Therapeutics position peaked at $1.33M in Q4 2023.
  • 22 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2024.

Based on Tang Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.